FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Fust Matthew K
2. Issuer Name and Ticker or Trading Symbol

Dermira, Inc. [ DERM ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150
3. Date of Earliest Transaction (MM/DD/YYYY)

9/12/2019
(Street)

MENLO PARK, CA 94025
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/12/2019    S    6000.00  D $8.7727 (1) 11051.00  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  This transaction was executed in multiple trades at prices ranging from $8.76 to $8.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Fust Matthew K
C/O DERMIRA, INC.
275 MIDDLEFIELD ROAD, SUITE 150
MENLO PARK, CA 94025
X



Signatures
/s/ Andrew L Guggenhime as attorney-in-fact 9/16/2019
**Signature of Reporting Person Date


Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Journey Medical Charts.
Journey Medical (NASDAQ:DERM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Journey Medical Charts.

Dermira, Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Tuesday 7 May 2024 (53 minutes ago) • GlobeNewswire Inc.
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
Wednesday 1 May 2024 (6 days ago) • GlobeNewswire Inc.
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
Thursday 25 April 2024 (2 weeks ago) • GlobeNewswire Inc.
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Thursday 21 March 2024 (2 months ago) • GlobeNewswire Inc.
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Monday 18 March 2024 (2 months ago) • GlobeNewswire Inc.
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Friday 15 March 2024 (2 months ago) • GlobeNewswire Inc.
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
Wednesday 13 March 2024 (2 months ago) • GlobeNewswire Inc.
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
Monday 11 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 4 - Statement of changes in beneficial ownership of securities
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Friday 5 January 2024 (4 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Tuesday 2 January 2024 (4 months ago) • Edgar (US Regulatory)
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Tuesday 2 January 2024 (4 months ago) • GlobeNewswire Inc.